124 related articles for article (PubMed ID: 38378696)
1. Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer.
Luzarraga Aznar A; Bebia V; López-Gil C; Villafranca-Magdalena B; Salazar-Huayna L; Castellvi J; Colàs E; Gil-Moreno A; Cabrera S
Int J Gynecol Cancer; 2024 May; 34(5):659-666. PubMed ID: 38378696
[TBL] [Abstract][Full Text] [Related]
2. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
3. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
4. Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis.
Luzarraga Aznar A; Bebia V; López-Gil C; Giraldo A; Montoya MP; Verges R; Jauregui A; Castellvi J; Pérez-Benavente A; Colás E; Gil-Moreno A; Cabrera S
Int J Gynecol Cancer; 2023 Oct; 33(10):1564-1571. PubMed ID: 37726197
[TBL] [Abstract][Full Text] [Related]
5. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study.
Ørtoft G; Lausten-Thomsen L; Høgdall C; Hansen ES; Dueholm M
J Gynecol Oncol; 2019 Sep; 30(5):e84. PubMed ID: 31328462
[TBL] [Abstract][Full Text] [Related]
6. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
7. Molecular and histopathologic predictors of distant failure in endometrial cancer.
Mariani A; Sebo TJ; Webb MJ; Riehle D; Katzmann JA; Keeney GL; Roche PC; Lesnick TG; Podratz KC
Cancer Detect Prev; 2003; 27(6):434-41. PubMed ID: 14642551
[TBL] [Abstract][Full Text] [Related]
8. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
Lindemann K; Kildal W; Kleppe A; Tobin KAR; Pradhan M; Isaksen MX; Vlatkovic L; Danielsen HE; Kristensen GB; Askautrud HA
Eur J Cancer; 2024 Mar; 200():113584. PubMed ID: 38330767
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of lymphovascular space invasion in patients with low-risk endometrial cancer.
Çakır İ; Gülseren V; Büyüktalancı E; Çakır ZE; Özer M; Ata C; Sancı M; Gökçü M; Erkılınç S; Güngördük K
Rev Assoc Med Bras (1992); 2023; 69(7):e20221730. PubMed ID: 37466592
[TBL] [Abstract][Full Text] [Related]
11. Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.
Chattopadhyay S; Cross P; Nayar A; Galaal K; Naik R
Int J Gynecol Cancer; 2013 May; 23(4):690-7. PubMed ID: 23518862
[TBL] [Abstract][Full Text] [Related]
12. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.
Gadducci A; Cavazzana A; Cosio S; DI Cristofano C; Tana R; Fanucchi A; Teti G; Cristofani R; Genazzani AR
Anticancer Res; 2009 May; 29(5):1715-20. PubMed ID: 19443392
[TBL] [Abstract][Full Text] [Related]
13. Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure.
Gadducci A; Cosio S; Fabrini MG; Fanucchi A; Barsotti C; Cristofani R; Greco C; Genazzani AR
Anticancer Res; 2011 Oct; 31(10):3483-8. PubMed ID: 21965765
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.
Jeans EB; Breen WG; Mullikin TC; Looker BA; Mariani A; Keeney GL; Haddock MG; Petersen IA
Int J Gynecol Cancer; 2021 Jun; 31(6):859-867. PubMed ID: 33563642
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
[TBL] [Abstract][Full Text] [Related]
16. Surgical stage I endometrial cancer: predictors of distant failure and death.
Mariani A; Webb MJ; Keeney GL; Lesnick TG; Podratz KC
Gynecol Oncol; 2002 Dec; 87(3):274-80. PubMed ID: 12468325
[TBL] [Abstract][Full Text] [Related]
17. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
18. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
19. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
20. The impact of tumor grade on survival end points and patterns of recurrence of 949 patients with early-stage endometrioid carcinoma: a single institution study.
Gayar OH; Patel S; Schultz D; Mahan M; Rasool N; Elshaikh MA
Int J Gynecol Cancer; 2014 Jan; 24(1):97-101. PubMed ID: 24264358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
